Ginkgo Bioworks (NYSE: DNA) insider plans 2,200-share sale
Rhea-AI Filing Summary
Ginkgo Bioworks Holdings, Inc. insider Austin Che filed a notice of proposed sale of 2,200 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $14,652.00 and 55,383,808 Class A shares reported outstanding as of August 17, 2026.
The shares derive from prior restricted stock vesting awards of 20 and 2,180 Class A shares that vested on October 10 and October 12, 2022, respectively. The filing also lists a sale of 2,200 Class A shares on June 10, 2026 for $17,732.00 during the past three months.
Positive
- None.
Negative
- None.
Key Figures
Planned shares to be sold: 2,200 Class A shares
Aggregate market value of planned sale: $14,652.00
Shares outstanding: 55,383,808 Class A shares
+3 more
6 metrics
Planned shares to be sold
2,200 Class A shares
Securities to be sold through Fidelity Brokerage Services LLC
Aggregate market value of planned sale
$14,652.00
Reported value for the 2,200 Class A shares to be sold
Shares outstanding
55,383,808 Class A shares
Reported outstanding as of August 17, 2026
Restricted stock vesting (Oct 10, 2022)
20 Class A shares
Restricted stock vesting from issuer as compensation
Restricted stock vesting (Oct 12, 2022)
2,180 Class A shares
Restricted stock vesting from issuer as compensation
Recent sale amount
2,200 Class A shares for $17,732.00
Securities sold during the past three months on June 10, 2026
Key Terms
Form 144, Restricted Stock Vesting, Compensation
3 terms
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Restricted Stock Vesting financial
"Restricted Stock Vesting | Issuer | | | 20 | 10/10/2022"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
Compensation financial
"10/12/2022 | Compensation"
FAQ
What does Ginkgo Bioworks (DNA) report in this Form 144 filing?
The filing reports a proposed sale of 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. by insider Austin Che. It lists the broker, expected aggregate value, prior restricted stock vesting awards, and a recent sale within the past three months.
What prior restricted stock vesting is disclosed for Ginkgo Bioworks (DNA) insider Austin Che?
Austin Che’s holdings include restricted stock awards of 20 and 2,180 Class A shares that vested on October 10, 2022 and October 12, 2022. These vestings are listed as compensation-related issuances from the issuer.
What recent sales of Ginkgo Bioworks (DNA) stock are reported for the past three months?
The filing lists a sale of 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. on June 10, 2026 for an aggregate value of $17,732.00. This is disclosed under securities sold during the past three months.
AI-generated analysis. How Rhea-AI works. Not financial advice.